Subtype
Genitourinary System Carcinoma
CI-CAN-00000925Explore in graph →
1,498 active trials44 approved drugs143 evidence items
- NCIt
- C164141
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000925Explore in graph →
Clinical trials
4,916 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (758)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05824975 | A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08) | recruiting | Phase 1 / Phase 2 | 358 | GI Innovation, Inc.INDUSTRY | 2 | Nov 25, 2024 | clinicaltrials |
| NCT05927818 | Sentinel Lymph Node Biopsy in Early-Stage Ovarian Cancer | recruiting | N/A | 100 | Istanbul UniversityOTHER | 1 | Nov 25, 2024 |
| clinicaltrials |
| NCT06632262 | A Phase 2 Clinical Study of ABSK061 and ABSK043 | recruiting | Phase 2 | 202 | Abbisko Therapeutics Co, LtdINDUSTRY | 1 | Nov 19, 2024 | clinicaltrials |
| NCT05572216 | A CCafU-UroCCR Randomized Trial: 3D Image-Guided Robot-AssisTEd Partial Nephrectomy for Renal Complex Tumor (UroCCR N°99)(ACCURATE) | recruiting | N/A | 694 | University Hospital, GrenobleOTHER | 1 | Nov 18, 2024 | clinicaltrials |
| NCT06639347 | A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma | recruiting | Phase 1 / Phase 2 | 90 | Shanghai Hengrui Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 18, 2024 | clinicaltrials |
| NCT04787042 | Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 | recruiting | Phase 1 / Phase 2 | 316 | Simcha IL-18, Inc.INDUSTRY | 1 | Nov 15, 2024 | clinicaltrials |
| NCT06690697 | Combination of Toripalimab and JS004 Therapy for ccRCC | recruiting | Phase 2 | 80 | Fudan UniversityOTHER | 1 | Nov 15, 2024 | clinicaltrials |
| NCT06686043 | HPV Vaccine, Imiquimod, and Metformin Combination Trial(HPV-VIM) | recruiting | Phase 2 | 85 | Baylor College of MedicineOTHER | 1 | Nov 13, 2024 | clinicaltrials |
| NCT06519760 | 68Ga-C1 PET/ CT Imaging in Clear Cell Renal Cell Carcinoma | recruiting | N/A | 200 | Peking University First HospitalOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT05001477 | Customized TULSA-PRO Ablation Registry(CARE) | recruiting | — | 1,000 | Profound Medical Inc.OTHER | 1 | Nov 6, 2024 | clinicaltrials |
| NCT06598761 | Postoperative Adjuvant Immunotherapy Combined with Radiotherapy Versus Surgery Alone in Locally Advanced UTUC | recruiting | — | 60 | Peking University First HospitalOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT05403554 | A Study of NI-1801 in Patients with Mesothelin Expressing Solid Cancers | recruiting | Phase 1 | 70 | Light Chain Bioscience - Novimmune SAINDUSTRY | 2 | Oct 29, 2024 | clinicaltrials |
| NCT05810571 | Comparison of Postoperative Analgesic Efficacy of the Erector Spina Plane Block and Quadratus Lumborum Block in Open Nephrectomy: a Prospective Randomized Clinical Study | recruiting | N/A | 60 | Kocaeli UniversityOTHER | 1 | Oct 26, 2024 | clinicaltrials |
| NCT06652009 | Radical Radiotherapy Versus Radical Surgery for UTUC | recruiting | — | 60 | Peking University First HospitalOTHER | 1 | Oct 22, 2024 | clinicaltrials |
| NCT06632431 | Clinicopathological Analysis of Endometrial Carcinoma in the View of Old and New International Federation of Gynecology and Obestetrics (FIGO) | recruiting | — | 110 | Assiut UniversityOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT06640348 | Ultrasensitive SERS Platform With Highly Efficient Enrichment of Analyte for Screening and Diagnosis of Epithelial Ovarian Cancer | recruiting | — | 70 | Anhui Provincial HospitalOTHER_GOV | 1 | Oct 15, 2024 | clinicaltrials |
| NCT05203913 | Cisplatin, Nab-paclitaxel, Nivolumab With Radiotherapy After Resection of Non-Metastatic Muscle Invasive Bladder Cancer(CNN-BC) | recruiting | Phase 2 | 32 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Oct 4, 2024 | clinicaltrials |
| NCT06613269 | 68Ga-NY104 PET/CT Guided Radiation Therapy in CcRCC.(NYCRRT) | recruiting | Phase 2 | 40 | Peking Union Medical College HospitalOTHER | 1 | Sep 27, 2024 | clinicaltrials |
| NCT06259552 | A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors(SPX-303) | recruiting | Phase 1 | 232 | SparX Biotech(Jiangsu) Co., Ltd.OTHER | 1 | Sep 24, 2024 | clinicaltrials |
| NCT06079112 | 9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer | recruiting | Phase 1 / Phase 2 | 100 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06184464 | Prostatic Size Reduction Following of Leuprorelin Acetate(PROSTSIZE) | recruiting | — | 40 | Consorci Sanitari de TerrassaOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06592326 | 9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer | recruiting | Phase 3 | 460 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06598176 | Developing a Combined Molecular Screening and Triage Test for Cervical Cancer in Self-samples(COMBISCREEN) | recruiting | N/A | 100 | Universiteit AntwerpenOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06585007 | Metastasis-directed Therapy in Oligoprogressive Castration-refractory Prostate Cancer(MEDCARE) | recruiting | Phase 3 | 246 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Sep 5, 2024 | clinicaltrials |
| NCT04665635 | Rectosigmoid Resection vs Seromuscular Tumor Shaving in Ovarian Cancer Surgery | recruiting | N/A | 120 | Cukurova UniversityOTHER | 1 | Aug 29, 2024 | clinicaltrials |
| NCT06378905 | Cukurova Score Validation Study(CUKUROVA) | recruiting | — | 130 | Cukurova UniversityOTHER | 1 | Aug 29, 2024 | clinicaltrials |
| NCT04498767 | Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE)(OligoRARE) | recruiting | N/A | 200 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 7 | Aug 26, 2024 | clinicaltrials |
| NCT01970696 | International Ovarian & Testicular Stromal Tumor Registry(OTST) | recruiting | — | 300 | Children's Hospitals and Clinics of MinnesotaOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT06343038 | Targeted Radionuclide Therapy in Metastatic Prostate Cancer Using a New PSMA Ligand Radiolabelled With Terbium-161 (161Tb-SibuDAB) - Dose Identification/Escalation Phase Ia/b Study(PROGNOSTICS) | recruiting | Phase 1 | 25 | University Hospital, Basel, SwitzerlandOTHER | 1 | Aug 14, 2024 | clinicaltrials |
| NCT06529549 | Efficacy and Safety of Organoid-Based Drug Sensitivity Screening to Guide the Treatment of mCRPC Patients Progressed After First-line Treatment | recruiting | — | 30 | Sun Yat-sen UniversityOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT06518226 | Two-Fraction Ultrahypofractionated Radiotherapy With Focal Boost for Intermediate Risk, Localized Prostate Cancer(TURBO) | recruiting | N/A | 160 | UMC UtrechtOTHER | 1 | Jul 24, 2024 | clinicaltrials |
| NCT06490211 | The Research Value of Multi-omics and Multi-modal Information in the Diagnosis and Treatment of Urinary System Tumors | recruiting | — | 100 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 8, 2024 | clinicaltrials |
| NCT06399419 | CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer | recruiting | Phase 1 | 28 | Osel, Inc.INDUSTRY | 1 | May 30, 2024 | clinicaltrials |
| NCT04694924 | Prospective Prostate Cancer and Patient-reported Outcomes Registry(Prosquare) | recruiting | — | 5,000 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | May 22, 2024 | clinicaltrials |
| NCT06420973 | RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression | recruiting | Phase 2 | 54 | Peking University Cancer Hospital & InstituteOTHER | 1 | May 20, 2024 | clinicaltrials |
| NCT06413992 | Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer | recruiting | Phase 2 | 117 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 14, 2024 | clinicaltrials |
| NCT06404671 | Timing of Surgery After Neoadjuvant Chemotherapy for Advanced Ovarian Cancer | recruiting | N/A | 250 | Alexandria UniversityOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT05868174 | Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX -Expressing Solid Tumors | recruiting | Phase 1 | 36 | Telix Pharmaceuticals (Innovations) Pty LimitedINDUSTRY | 1 | May 1, 2024 | clinicaltrials |
| NCT06391190 | Concurrent Chemoradiotherapy Followed by PD-1 Inhibitor in Advanced Cervical Cancer | recruiting | Phase 1 / Phase 2 | 20 | RenJi HospitalOTHER | 1 | Apr 30, 2024 | clinicaltrials |
| NCT03749980 | MyVHL: Patient Natural History Study(MyVHL) | recruiting | — | 10,000 | Joshua Mann, MPHOTHER | 1 | Apr 26, 2024 | clinicaltrials |
| NCT04641936 | Urine Omics Predicting IO Therapy Responses in mUC Patients | recruiting | — | 600 | National Taiwan University HospitalOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT05905315 | Primary Chemoradiation VS. Neoadjuvant Chemotherapy Followed By Surgery As Treatment Strategy For LAVC(VULCANIZE-II) | recruiting | Phase 2 | 98 | The Netherlands Cancer InstituteOTHER | 1 | Apr 15, 2024 | clinicaltrials |
| NCT04838899 | Stereotactic Ablative Radiation Therapy for Abiraterone-Resistant, Oligoprogressive Metastatic Prostate Cancer | recruiting | N/A | 30 | Sunnybrook Health Sciences CentreOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT05080556 | Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer(ACTOv) | recruiting | Phase 2 | 80 | University College, LondonOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT06354231 | DV Combined With Toripalimab for Renal Preservation in Solitary Kidney or Renal Insufficiency or Bilateral Multiple UTUC | recruiting | Phase 2 | 20 | Fudan UniversityOTHER | 1 | Apr 11, 2024 | clinicaltrials |
| NCT06336187 | European Active Surveillance of Renal Cell Carcinoma Study (EASE RCC Study)(EASE) | recruiting | — | 400 | Azienda Ospedaliero Universitaria Maggiore della CaritaOTHER | 1 | Apr 10, 2024 | clinicaltrials |
| NCT06341907 | Application of MRD Combined With Personalized Vaccine in the Treatment of Postoperative Recurrence Prevention of EOC | recruiting | Phase 2 / Phase 3 | 10 | Second Affiliated Hospital of Wenzhou Medical UniversityOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT06265025 | GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 125 | GeneMedicine Co., Ltd.INDUSTRY | 1 | Mar 21, 2024 | clinicaltrials |
| NCT06321679 | Response Evaluation of Cancer Therapeutics in Metastatic Castration-Resistant Prostate Cancer to the Bone(RESPECT) | recruiting | — | 40 | European Institute of OncologyOTHER | 1 | Mar 20, 2024 | clinicaltrials |
| NCT06292897 | Using Tissue-based Spatial Data to Understand How Obesity-related Tumor Metabolites Fuel Prostate Cancer Progression(OBESITA'&PCa) | recruiting | — | 25 | Fondazione IRCCS Ca' Granda, Ospedale Maggiore PoliclinicoOTHER | 1 | Mar 5, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Nov 25, 2024source: clinicaltrials